NY-198の抗菌力ならびに臨床効果に関する検討

DOI

書誌事項

タイトル別名
  • ANTIMICROBIAL ACTIVITY AND CLINICAL EFFECT OF NY-198

抄録

We performed laboratory and clinical studies on a new pyridone carboxylic acid, NY-198, and the results were as follows.<BR>1) Antimicrobial activity<BR>MICs of NY-198 against 393 clinically isolated strains of 29 species were measured and compared with those of CPFX, ENX, OFLX, NFLX, PPA, PA and NA. In general, antimicrobial activity of the new quinolones against Gram-positive cocci was slightly weak, and that of NY-198 was even weaker than the other drugs. On the other hand, NY-198 showed favorable activity against Enterobacteriaceae and other Gram-negative bacilli, except for strains of P. cepacia and X. maltophilia. Its activity was similar to that of ENX, and inferior to those of the other new quinolones.<BR>2) Clinical effect<BR>We studied the clinical efficacy of NY-198 in 12 patients with respiratory tract infection (7 cases of pneumonia, 3 of chronic bronchitis, 1 case of bronchiectasis and 1 of DPB), 1 case of urinary tract infection, 1 case of bacteremia and 1 case of acute enterocolitis. The drug was administered at a daily dose of 300-600 mg for 7-22 days. Excellent or good response was shown in 14 patients. Of the strains isolated, bacteriologicalactivity of the drug was inadequate against S. pneumoniae, but strong against S. epidermidis, P. aeruginosa and P. mirabilis<.<BR>No side-effects of NY-198 were observed, but transient elevation of GPT and Al-P values was recognized in one case each.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ